[조사 보고서] 세계의 항체 약물 접합체 (ADC) 시장 2024-2030 : 용도별 (혈액암, 유방암), 기술별 (절단 가능, 절단 불가능), 제품별, 대상별, 지역별

■ 영문 제목 : Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030
	■ 상품코드 : GRV24MAY100 ■ 조사/발행회사 : Grand View Research ■ 발행일 : 2024년 4월 ■ 페이지수 : 125 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (2일 소요) ■ 조사대상 지역 : 세계 ■ 산업 분야 : 의료/바이오

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User (1인 열람용)	USD5,950 ⇒환산￦8,330,000	견적의뢰/주문/질문
Multi User (5인 열람용)	USD6,950 ⇒환산￦9,730,000	견적의뢰/주문/질문
Global/corporate License (기업 열람용)	USD8,950 ⇒환산￦12,530,000	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

글로벌 항체 약물 접합체 (ADC) 시장의 성장과 동향

Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 항체 약물 접합체 (ADC) 시장 규모는 2030년까지 240억 1000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 9. 2%의 성장률을 기록할 것으로 전망됩니다. 강력한 파이프라인 제품의 존재와 주요 기업의 전략적 이니셔티브가 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

ADC Therapeutics, Seagen, Takeda Pharmaceuticals, F. Hoffman-La Roche, AstraZeneca, Daiichi Sankyo 등 주요 기업들은 제품 개발 및 상용화를 위한 공동 연구를 진행하고 있습니다. 예를 들어, 2022년 2월 메르사나 테라퓨틱스는 존슨앤드존슨의 자회사인 얀센 파마슈티컬 컴퍼니즈(Janssen Pharmaceutical Companies)와 다양한 암을 치료하는 새로운 ADC의 연구개발을 위해 협력하기로 했습니다. 이번 계약에 따라 얀센은 메르사나 테라퓨틱에 계약금 4,000만 달러와 신규 ADC 개발에 대한 마일스톤으로 10억 달러 이상을 지급할 수 있습니다.

제약사들의 신규 항체 약물 접합체 (ADC) 개발에 대한 광범위한 연구와 자금 조달 증가는 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2021년 4월에 두 개의 신생 기업인 Adcendo와 Adcentrx는 암 치료에 대한 새로운 접근 방식을 통한 ADC 개발을 위해 약 1억 1,200만 달러의 자금을 조달했습니다. 애드센도는 약물 전달체 역할을 하는 내피세포 수용체를 표적으로 하는 새로운 ADC 개발을 위해 5,100만 달러를, Adcentrx는 ADC 연구 프로그램을 위해 5,000만 달러의 자금을 조달했습니다.

또한 2022년 3월, 이뮤노젠은 미국 FDA에 난소암 환자의 단독 요법으로 사용되는 밀베툭시맙 솔라브탄신의 생물학적 제제 허가 신청서(BLA)를 제출했다고 발표했습니다. 이 제제는 α-결합 항체, 분열 가능한 링커, 메이탄시노이드 DM4로 구성되어 표적 암세포를 죽이는 역할을 합니다.

ADC에 대한 엄격한 상환 정책은 단클론 항체 치료 및 화학 요법과 같은 대체 기존 치료법에 비해 ADC 치료와 관련된 높은 비용으로 인해 시장 성장을 저해할 수 있습니다. 이러한 높은 치료비용이 상환에 걸림돌이 될 것으로 예상됩니다. 예를 들어, 2020년 2월 아일랜드의 National Centre for Pharmaco economics는 로슈의 Kadcyla(trastuzumab emtansine)에 대해 비용 대비 효과가 낮다는 이유로 부정적인 검토를 내렸습니다.

고령 인구의 증가와 다발성 골수종(MM)과 같은 질환의 유병률 증가는 ADC에 대한 수요를 촉진하고 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 다발성 골수종(MM)은 고령화 사회의 질병으로, 2021년에는 30,000명에 가까운 MM 신규 환자가 진단될 것으로 예상됩니다. 다발성 골수종 진단을 받은 환자의 평균 연령은 70세입니다. 따라서 다발성 골수종 치료에 새로운 ADC가 도입되면 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2020년 8월 FDA는 글락소 스미스클라인의 BLENREP을 재발성 또는 불응성 다발성 골수종에 대한 단독요법으로 승인했습니다. 블렌렙은 다발성 골수종 치료제로 승인된 최초의 항 BCMA 치료법입니다.

항체 약물 접합체 (ADC) 시장 보고서 하이라이트

- 유방암의 높은 유병률과 다양한 유방암 치료용 ADC 제품의 출시로 2023년 유방암이 47. 76%의 매출 점유율을 차지할 것으로 예상됩니다.

- 시판 중인 ADC 제품에서 개질성 링커 기술의 채택이 증가하고 다른 링커 기술보다 개질성 링커 사용과 관련된 이점이 있어 개질성 링커 부문이 2023년 72. 43%로 가장 큰 매출 점유율을 차지할 것으로 예상됩니다.

- 링커 기술 유형별로는 SMCC, SPP, MCC, 말레이미드 테트라펩타이드, CL2A, MC(말레이미드 카프로일) 등 페이로드를 표적 부위에 전달하는 데 사용되는 매우 효과적인 링커가 다수 존재하기 때문에 기타 분야가 시장을 지배하고 있습니다.

- 북미는 화이자, 길리어드 라이프 사이언스, 세겐 등 주요 제약사의 존재와 신규 ADC 개발을 위한 전략적 이니셔티브로 인해 2023년 매출 점유율 52. 54%를 차지할 것으로 예상됩니다.

■ 보고서 개요

1. 조사 방법 및 범위
2. 개요
3. 시장 변수, 동향, 범위
4. 세계의 항체 약물 접합체 (ADC) 시장 용도별 세그먼트 분석, 2018-2030년
5. 세계의 항체 약물 접합체 (ADC) 시장 제품별 세그먼트 분석, 2018-2030년
6. 세계의 항체 약물 접합체 (ADC) 시장 대상별 세그먼트 분석, 2018-2030년
7. 세계의 항체 약물 접합체 (ADC) 시장 기술별 세그먼트 분석, 2018-2030년
8. 세계의 항체 약물 접합체 (ADC) 시장 지역별 분석, 2018-2030년
9. 경쟁 현황

■ 보고서 목차

Table of Contents

Chapter 1. Methodology And Scope
1.1 Market Segmentation And Scope
1.1.1 Segment Definitions
1.1.1.1 Application Segment
1.1.1.2 Technology Segment
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 GVR’ s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Technology And Application Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation And Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends And Outlook
3.4. Market Dynamics
3.4.1. Presence Of Strong Product Pipeline
3.4.2. Growing Geriatric Population Base
3.4.3. Increasing Incidence And Prevalence Of Cancer
3.5. Market Restraint Analysis
3.5.1. High Manufacturing Cost And Downstream Processing Challenges For ADCs
3.5.2. Analytical Challenges For ADCs
3.5.3. Stringent Reimbursement Policies For ADCs
3.6. Business Environment Analysis
3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. Covid-19 Impact Analysis
3.7. Qualitative Analysis For ADC Development Platforms
3.7.1. Creative Biolabs
3.7.2. Mersana Therapeutics
3.7.3. Heidelberg Pharma
3.7.4. Synaffix BV
3.7.5. NBE Therapeutics
3.7.6. VERAXA
3.7.7. Tubulis Gmbh
3.7.8. Byondis Platform
3.7.9. Immunogen, Inc.
3.7.10. RemeGen
3.7.11. Wuxi Biologics
3.7.12. Merck & Co., Inc.
3.7.13. Ambrx
Chapter 4. Antibody Drug Conjugates Market: Segment Analysis By Application, 2018 – 2030 (USD Million)
4.1. Antibody Drug Conjugates Market: Application Movement Analysis
4.2. Blood Cancer
4.2.1. Blood Cancer Market, 2018 – 2030 (USD Million)
4.2.2. Leukemia
4.2.2.1. Leukemia Market, 2018 – 2030 (USD Million)
4.2.3. Multiple Myeloma
4.2.3.1. Multiple Myeloma Market, 2018 – 2030 (USD Million)
4.2.4. Lymphoma
4.2.4.1. Lymphoma Market, 2018 – 2030 (USD Million)
4.3. Breast Cancer
4.4. Urothelial/Bladder Cancer
4.4.1. Urothelial/Bladder Cancer Market, 2018 – 2030 (USD Million)
4.5. Others
4.5.1. Others Market, 2018 – 2030 (USD Million)
Chapter 5. Antibody Drug Conjugates Market: Segment Analysis By Product, 2018 – 2030 (USD Million)
5.1. Antibody Drug Conjugates Market: Product Movement Analysis
5.2. Kadcyla
5.2.1. Kadcyla Market, 2018 – 2030 (USD Million)
5.3. Enhertu
5.3.1. Enhertu Market, 2018 – 2030 (USD Million)
5.4. Adcetris
5.4.1. Adcetris Market, 2018 – 2030 (USD Million)
5.5. Padcev
5.5.1. Padcev Market, 2018 – 2030 (USD Million)
5.6. Polivy
5.6.1. Polivy Market, 2018 – 2030 (USD Million)
5.7. Others
5.7.1. Others Market, 2018 – 2030 (USD Million)
Chapter 6. Antibody Drug Conjugates Market: Segment Analysis By Target, 2018 – 2030 (USD Million)
6.1. Antibody Drug Conjugates Market: Target Movement Analysis
6.2. HER2
6.2.1. HER2 Market, 2018 – 2030 (USD Million)
6.3. CD22
6.3.1. CD22 Market, 2018 – 2030 (USD Million)
6.4. CD30
6.4.1. CD30 Market, 2018 – 2030 (USD Million)
6.5. Others
6.5.1. Others market, 2018 – 2030 (USD Million)
Chapter 7. Antibody Drug Conjugates Market: Segment Analysis By Technology, 2018 – 2030 (USD Million)
7.1. Antibody Drug Conjugates Market: Technology Movement Analysis
7.2. By Type
7.2.1. Cleavable Linker
7.2.1.1. Cleavable Linker Market, 2018 – 2030 (USD Million)
7.2.2. Non-Cleavable Linker
7.2.2.1. Non-Cleavable Linker Market, 2018 – 2030 (USD Million)
7.2.3. Linkerless
7.2.3.1. Linkerless Market, 2018 – 2030 (USD Million)
7.3. By Linker Technology
7.3.1. Vc (Valine-Citrulline)
7.3.1.1. Vc Market, 2018 – 2030 (USD Million)
7.3.2. Sulfo-SPDB
7.3.2.1. Sulfo-SPDB Market, 2018 – 2030 (USD Million)
7.3.3. VA (Valine Alanine)
7.3.3.1. VA (Valine Alanine) Market, 2018 – 2030 (USD Million)
7.3.4. Hydrazone
7.3.4.1. Hydrazone Market, 2018 – 2030 (USD Million)
7.3.5. Others
7.3.5.1. Others Market, 2018 – 2030 (USD Million)
7.4. By Payload Technology
7.4.1. MMAE
7.4.1.1. MMAE Market, 2018 – 2030 (USD Million)
7.4.2. MMAF
7.4.2.1. MMAF Market, 2018 – 2030 (USD Million)
7.4.3. Dm4
7.4.3.1. Dm4 Market, 2018 – 2030 (USD Million)
7.4.4. Camptothecin
7.4.4.1. Camptothecin Market, 2018 – 2030 (USD Million)
7.4.5. Others
7.4.5.1. Others Market, 2018 – 2030 (USD Million)
Chapter 8. Antibody Drug Conjugates Market: Regional Analysis, 2018 – 2030 (USD Million)
8.1. Antibody Drug Conjugates Market Share By Region, 2022 & 2030
8.2. North America
8.2.1. Swot Analysis
8.2.2. North America Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.2.3. U.S.
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. U.S. Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.2.4. Canada
8.2.4.1. Key Country Dynamics
8.2.4.2. Target Disease Prevalence
8.2.4.3. Competitive Scenario
8.2.4.4. Regulatory Framework
8.2.4.5. Reimbursement Scenario
8.2.4.6. Canada Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.3. Europe
8.3.1. Swot Analysis
8.3.2. Europe Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.3.6. Germany Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.3.4. UK
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.4.6. UK Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.3.5. France
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.5.6. France Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.3.6. Italy
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.6.6. Italy Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.3.7. Spain
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.7.6. Spain Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.3.8. Denmark
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.3.8.6. Denmark Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Reimbursement Scenario
8.3.9.6. Sweden Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.3.10. Norway
8.3.10.1. Key Country Dynamics
8.3.10.2. Target Disease Prevalence
8.3.10.3. Competitive Scenario
8.3.10.4. Regulatory Framework
8.3.10.5. Reimbursement Scenario
8.3.10.6. Norway Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Swot Analysis
8.4.2. Asia Pacific Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.4.3. Japan
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.3.6. Japan Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.4.4. China
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.4.4.6. China Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.4.5. India
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. Reimbursement Scenario
8.4.5.6. India Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.4.6. South Korea
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Reimbursement Scenario
8.4.6.6. South Korea Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.4.7. Australia
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Reimbursement Scenario
8.4.7.6. Australia Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.4.8. Thailand
8.4.8.1. Key Country Dynamics
8.4.8.2. Target Disease Prevalence
8.4.8.3. Competitive Scenario
8.4.8.4. Regulatory Framework
8.4.8.5. Reimbursement Scenario
8.4.8.6. Thailand Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.5. Latin America
8.5.1. Swot Analysis
8.5.2. Latin America Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.5.3. Brazil
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.3.6. Brazil Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.5.4. Mexico
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Reimbursement Scenario
8.5.4.6. Mexico Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.5.5. Argentina
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Competitive Scenario
8.5.5.4. Regulatory Framework
8.5.5.5. Reimbursement Scenario
8.5.5.6. Argentina Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.8. Middle East and Africa (MEA)
8.8.1. Swot Analysis
8.8.2. MEA Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.8.3. South Africa
8.8.3.1. Key Country Dynamics
8.8.3.2. Target Disease Prevalence
8.8.3.3. Competitive Scenario
8.8.3.4. Regulatory Framework
8.8.3.5. Reimbursement Scenario
8.8.3.6. South Africa Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.8.4. Saudi Arabia
8.8.4.1. Key Country Dynamics
8.8.4.2. Target Disease Prevalence
8.8.4.3. Competitive Scenario
8.8.4.4. Regulatory Framework
8.8.4.5. Reimbursement Scenario
8.8.4.6. Saudi Arabia Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.8.5. UAE
8.8.5.1. Key Country Dynamics
8.8.5.2. Target Disease Prevalence
8.8.5.3. Competitive Scenario
8.8.5.4. Regulatory Framework
8.8.5.5. Reimbursement Scenario
8.8.5.6. UAE Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
8.8.6. Kuwait
8.8.6.1. Key Country Dynamics
8.8.6.2. Target Disease Prevalence
8.8.6.3. Competitive Scenario
8.8.6.4. Regulatory Framework
8.8.6.5. Reimbursement Scenario
8.8.6.6. Kuwait Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1 Company Categorization
9.2 Strategy Mapping
9.2.1 New Product Launch
9.2.2 Partnerships
9.2.3 Acquisition
9.2.4 Collaboration
9.2.5 Funding
9.3 Key Company Market Share Analysis, 2023
9.4 Company Profiles
9.4.1 Takeda Pharmaceutical Company Limited
9.4.1.1 Company Overview
9.4.1.2 Financial Performance
9.4.1.3 Product Benchmarking
9.4.1.4 Strategic Initiatives
9.4.2 F.Hoffmann-La Roche Ltd.
9.4.2.1 Company Overview
9.4.2.2 Financial Performance
9.4.2.3 Product Benchmarking
9.4.2.4 Strategic Initiatives
9.4.3 Pfizer, Inc.
9.4.3.1 Company Overview
9.4.3.2 Financial Performance
9.4.3.3 Product Benchmarking
9.4.3.4 Strategic Initiatives
9.4.4 Astrazeneca
9.4.4.1 Company Overview
9.4.4.2 Product Benchmarking
9.4.4.3 Strategic Initiatives
9.4.5 Gilead Sciences, Inc.
9.4.5.1 Company Overview
9.4.5.2 Financial Performance
9.4.5.3 Product Benchmarking
9.4.5.4 Strategic Initiatives
9.4.6 Astellas Pharma Inc.
9.4.6.1 Company Overview
9.4.6.2 Financial Performance
9.4.6.3 Product Benchmarking
9.4.6.4 Strategic Initiatives
9.4.7 Seagen, Inc.
9.4.7.1 Company Overview
9.4.7.2 Financial Performance
9.4.7.3 Product Benchmarking
9.4.7.4 Strategic Initiatives
9.4.8 Daiichi Sankyo Company, Limited
9.4.8.1 Company Overview
9.4.8.2 Financial Performance
9.4.8.3 Product Benchmarking
9.4.8.4 Strategic Initiatives
9.4.9 Glaxosmithkline Plc.
9.4.9.1 Company Overview
9.4.9.2 Financial Performance
9.4.9.3 Product Benchmarking
9.4.9.4 Strategic Initiatives
9.4.10 Adc Therapeutics Sa
9.4.10.1 Company Overview
9.4.10.2 Financial Performance
9.4.10.3 Product Benchmarking
9.4.10.4 Strategic Initiatives
9.4.11 Synaffix Bv
9.4.11.1 Company Overview
9.4.11.2 Financial Performance
9.4.11.3 Product Benchmarking
9.4.11.4 Strategic Initiatives
Chapter 10. Kol Recommendations/ Conclusion

List of Tables

TABLE 1 List of abbreviation
TABLE 2 List of secondary sources
TABLE 3 Global antibody-drug conjugates market estimates and forecasts, by region, 2018 - 2030 (USD Million)
TABLE 4 Global antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 5 Global antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 6 Global antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 7 Global antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 8 Global antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 9 Global antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 10 North America antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
TABLE 11 North America antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 12 North America antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 13 North America antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 14 North America antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 15 North America antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 16 North America antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 17 U.S. antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 18 U.S. antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 19 U.S. antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 20 U.S. antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 21 U.S. antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 22 U.S. antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 23 Canada antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 24 Canada antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 25 Canada antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 26 Canada antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 27 Canada antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 28 Canada antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 29 Europe antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
TABLE 30 Europe antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
TABLE 31 Europe antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 32 Europe antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 33 Europe antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 34 Europe antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 35 Europe antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 36 Europe antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 37 UK antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 38 UK antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 39 UK antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 40 UK antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 41 UK antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 42 UK antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 43 Germany antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 44 Germany antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 45 Germany antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 46 Germany antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 47 Germany antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 48 Germany antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 49 France antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 50 France antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 51 France antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 52 France antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 53 France antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 54 France antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 55 Italy antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 56 Italy antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 57 Italy antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 58 Italy antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 59 Italy antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 60 Italy antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 61 Spain antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 62 Spain antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 63 Spain antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 64 Spain antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 65 Spain antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 66 Spain antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 67 Denmark antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 68 Denmark antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 69 Denmark antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 70 Denmark antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 71 Denmark antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 72 Denmark antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 73 Sweden antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 74 Sweden antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 75 Sweden antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 76 Sweden antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 77 Sweden antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 78 Sweden antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 79 Norway antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 80 Norway antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 81 Norway antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 82 Norway antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 83 Norway antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 84 Norway antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 85 Asia Pacific antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 86 Asia Pacific antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 87 Asia Pacific antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 88 Asia Pacific antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 89 Asia Pacific antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 90 Asia Pacific antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 91 Japan antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 92 Japan antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 93 Japan antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 94 Japan antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 95 Japan antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 96 Japan antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 97 China antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 98 China antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 99 China antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 100 China antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 101 China antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 102 China antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 103 India antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 104 India antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 105 India antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 106 India antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 107 India antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 108 India antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 109 Australia antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 110 Australia antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 111 Australia antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 112 Australia antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 113 Australia antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 114 Australia antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 115 South Korea antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 116 South Korea antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 117 South Korea antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 118 South Korea antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 119 South Korea antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 120 South Korea antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 121 Thailand antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 122 Thailand antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 123 Thailand antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 124 Thailand antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 125 Thailand antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 126 Thailand antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 127 Latin America antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 128 Latin America antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 129 Latin America antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 130 Latin America antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 131 Latin America antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 132 Latin America antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 133 Brazil antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 134 Brazil antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 135 Brazil antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 136 Brazil antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 137 Brazil antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 138 Brazil antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 139 Mexico antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 140 Mexico antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 141 Mexico antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 142 Mexico antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 143 Mexico antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 144 Mexico antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 145 Argentina antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 146 Argentina antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 147 Argentina antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 148 Argentina antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 149 Argentina antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 150 Argentina antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 151 MEA antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 152 MEA antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 153 MEA antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 154 MEA antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 155 MEA antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 156 MEA antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 157 South Africa antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 158 South Africa antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 159 South Africa antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 160 South Africa antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 161 South Africa antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 162 South Africa antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 163 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 164 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 165 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 166 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 167 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 168 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 169 UAE antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 170 UAE antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 171 UAE antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 172 UAE antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 173 UAE antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 174 UAE antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 175 Kuwait antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 176 Kuwait antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 177 Kuwait antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 178 Kuwait antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 179 Kuwait antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 180 Kuwait antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 181 List of key distributors
TABLE 182 List of key emerging companies/technology disruptors/innovators

※본 조사보고서 [세계의 항체 약물 접합체 (ADC) 시장 2024-2030 : 용도별 (혈액암, 유방암), 기술별 (절단 가능, 절단 불가능), 제품별, 대상별, 지역별] (코드 : GRV24MAY100) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [세계의 항체 약물 접합체 (ADC) 시장 2024-2030 : 용도별 (혈액암, 유방암), 기술별 (절단 가능, 절단 불가능), 제품별, 대상별, 지역별] 에 대해서 E메일 문의는 여기를 클릭하세요.

*** 아래는 관련 보고서 소개입니다 ***

세계의 생물 촉진제 시장 (2023-2030) : 유효 성분별 (산기반, 미생물), 작물 종류별, 용도별 (엽면 처리, 토양 처리), 지역별
GRV23MA013 / Grand View Research / 2023년 1월 / Grand View Research사는 글로벌 생물 촉진제 시장 규모가 2023년부터 2030년 사이에 연평균 7.4% 성장하여, 2030년에는 46억 달러에 달할 것으로 전망하고 있습니다. 본 조사 자료는 글로벌 생물 촉진제 시장을 조사대상으로 하여,...Biostimulants Market Growth & Trends The global biostimulants market size is expected to reach USD 4.6 billion by 2030, as per the new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.4% from 2023 to 2030. This is attributable to surging consumption...

세계의 심혈관용 디지털 솔루션 시장 (2023-2030) : 서비스 종류별 (비침습 검사, CVD 헬스 인포매틱스), 컴포넌트별, 전개별, 최종 용도별, 지역별
GRV23MR063 / Grand View Research / 2023년 2월 / Grand View Research사의 본 조사 보고서는 글로벌 심혈관용 디지털 솔루션 시장 규모가 2023년부터 2030년 사이에 CAGR 4.8% 증가하여, 2030년에는 1,486억 달러에 이를 것으로 예측하고 있습니다. 본 조사 자료는 글로벌 심혈관용...Cardiovascular Digital Solutions Market Growth & Trends The global cardiovascular digital solutions market size is expected to reach USD 148.6 billion by 2030 to expand at a CAGR of 4.8% from 2023 to 2030 based on a new report by Grand View Research, Inc. The increasing prevalence of cardiovascular diseases...

세계의 전이성 간암 치료 시장 (2023-2030) : 치료 종류별 (화학 요법, 면역 요법, 표적 요법), 원발암별 (대장암, 유방암), 유통 채널별, 지역별
GRV23MR114 / Grand View Research / 2023년 2월 / Grand View Research사의 본 조사 보고서는 글로벌 전이성 간암 치료 시장 규모가 2023년부터 2030년 사이에 CAGR 7.2% 증가하여, 2030년에는 23.1억 달러에 달할 것으로 전망하고 있습니다. 본 조사 자료는 글로벌 전이성...Liver Metastases Treatment Market Growth & Trends The global liver metastases treatment market is expected to reach USD 2.31 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 7.2% from 2023 to 2030. Rising prevalence of target disease, advanced stage diagnosis...

세계의 비침습적 지방 제거 시장 (2023-2030) : 기술별 (냉동 지방 분해술, 초음파), 최종 용도별 (병원, 독립 진료소, 다중 전문 진료소), 지역별
GRV23NOV217 / Grand View Research / 2023년 9월 / 글로벌 비침습적 지방 제거 시장의 성장과 동향 Grand View Research사의 새로운 보고서에 따르면, 세계의 비침습적 지방 제거 시장 규모는 예측 기간 동안 16. 2%의 CAGR을 기록하며 2030년까지 43억 달러에 달할...Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변동, 동향, 범위 Chapter 4. 세계의 비침습적 지방 제거 시장 : 기술별 예측 및 동향 분석 Chapter 5. 세계의 비침습적 지방 제거 시장 : 최종 용도별 예측 및 동향 분석 Chapter 6. 세계의 비침습적 지방 제거 시장 :...

세계의 메타게노믹스 시장 2024-2030 : 기술별 (샷건 시퀀싱, 전체 게놈 시퀀싱), 제품별, 워크플로우별, 용도별, 지역별
GRV24MAY127 / Grand View Research / 2024년 4월 / 글로벌 메타게노믹스 시장의 성장과 동향 Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 메타게노믹스 시장 규모는 2030년까지 48억 2천만 달러에 달하며, 2024년부터 2030년까지 13. 52%의 CAGR로 성장할 것으로 예상됩니다. 유전체학...1. 조사 방법 및 범위 2. 개요 3. 시장 변수, 동향, 범위 4. 세계의 메타게노믹스 시장 제품별 비즈니스 분석 5. 세계의 메타게노믹스 시장 기술별 비즈니스 분석 6. 세계의 메타게노믹스 시장 워크플로우 비즈니스 분석 7. 세계의 메타게노믹스 시장 용도별 비즈니스 분석 8. 세계의 메타게노믹스 시장 지역별 비즈니스 분석 9. 경쟁 현황...

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!